This Plain Language Summary of Publication article (PLSP) from Immunotherapy, highlights key published information about omalizumab and its use in chronic spontaneous urticaria (CSU). CSU is a long-term skin condition causing itchy hives and swelling for over six weeks without a clear trigger, often affecting daily life. Many people with CSU are treated with omalizumab (Xolair®), a medicine that works by blocking a blood protein called IgE.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status’ and was published in Dermatology and Therapy.

Visit SpringerNature Link using the link to read the original article.